Phase 2 Clinical Trial

Innovent Biologics presented positive Phase 2 results for tigulixostat (IBI128), a xanthine oxidase inhibitor for gout, at APLAR 2025. The study (NCT06501534) in Chinese patients showed tigulixostat significantly reduced serum uric acid levels compared to febuxostat, with a favorable safety profile and no serious adverse events. Innovent plans to initiate Phase 3 trials in China in the second half of 2025, aiming to address the unmet need for safer and more effective gout treatments amidst concerns about existing therapies.